Adagio medical announces completion of first procedures in fulcrum-vt u.s. fda pivotal ide of ventricular tachycardia cryoablation system

Laguna hills, calif.--(business wire)--adagio medical holdings, inc. (nasdaq: adgm; “adagio medical”, “adagio” or the “company”), a leading innovator in catheter ablation technologies, today announced the completion of the first procedures in fulcrum-vt u.s. food and drug administration (fda) pivotal ide study of adagio's vt cryoablation system. procedures were performed by professor william g. stevenson, md, at vanderbilt university medical center in nashville, tn and dr. j. david burkhardt at.
ADGM Ratings Summary
ADGM Quant Ranking